Biocartis Group NV (BCART.BR)
- GlobeNewswire
Press release Biocartis Group NV: Disclosure of transparency notification
PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium, 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous prov
- GlobeNewswire
Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test
PRESS RELEASE 2 March 2023, 7:00 CET BIOCARTIS ANNOUNCES THE US FDA 510(k) CLEARANCE FOR THE IDYLLA™ MSI TEST Mechelen, Belgium, 2 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance1 for its fully automated Idylla™ MSI Test. This 510(k) clearance reinforces Biocartis’ commitment to enable clinical molecular diagnostics in the U.S. Now,
- GlobeNewswire
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
PRESS RELEASE - REGULATED INFORMATION 28 February 2023, 17:50 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 28 February 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of February 2023 4.50% convertible bonds due 2026 in a principal amount of EUR 1,800 were converted into shares of the Company against the issuance of in total 1,613 shares of the Company. On 24
